文献速递角膜与眼表疾病

Reproxalap在干眼病2b期随机双盲赋形剂对照试验中起效早且活性广泛

Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
PubMed 文献 · Am J Ophthalmol · 2021-01-30

PURPOSE: To assess the activity of reproxalap, a novel reactive aldehyde species (RASP) inhibitor, relative to vehicle in patients with dry eye disease (DED) DESIGN: Randomized, double-masked, vehicle-controlled Phase 2b trial METHODS: Three hundred patients with DED were randoml…

要点

  • 0.25% reproxalap在眼干涩症状和鼻区荧光素染色上显著优于赋形剂。
  • 12周治疗期间安全性指标未见显著变化。

核心结论

  • 新型RASP抑制剂reproxalap在12周治疗中表现出快速、广泛且具临床相关性的症状控制,并在荧光素染色体征上显著优于赋形剂。

主要发现

  • 观察到干眼病体征和症状的剂量反应关系。
  • 安全性指标未见显著变化。

临床怎么用

  • 对于干眼病患者,0.25% reproxalap每日四次治疗12周可能改善眼干涩症状和鼻区荧光素染色体征,且安全性指标未见显著变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the activity of reproxalap, a novel reactive aldehyde species (RASP) inhibitor, relative to vehicle in patients with dry eye disease (DED) DESIGN: Randomized, double-masked, vehicle-controlled Phase 2b trial METHODS: Three hundred patients with DED were randomly assigned 1:1:1 at multiple US sites to receive 0.1% topical ocular reproxalap, 0.25% topical ocular reproxalap, or vehicle. Eyes were treated bilaterally 4 times daily for 12 weeks. Standard signs and symptoms of DED were assessed at baseline and at Weeks 2, 4, 8, and 12. RESULTS: A dose response was observed for signs and symptoms of DED. Relative to vehicle over 12 weeks of therapy, the largest symptomatic improvement was observed in ocular dryness (0.25%, P = .047), and the largest objective sign improvement was observed in nasal region fluorescein staining (0.25%, P = .030). A greater proportion of patients receiving 0.25% reproxalap vs. vehicle reported dryness scores of 0 (P = .012). Improvements in combined DED symptoms were evident by the first post-baseline visit (Week 2, 0.25%, P < .0001) in patients with baseline scores greater than or equal to median values. No significant changes in safety measures were observed. CONCLUSION: The novel RASP inhibitor reproxalap demonstrated rapid, broad, and clinically relevant symptomatic control, in conjunction with statistically significant improvement over vehicle in signs of DED as demonstrated by fluorescein staining, in DED patients over 12 weeks of therapy. The results represent the first vehicle-controlled evidence for the therapeutic potential of RASP inhibition to mitigate the signs and symptoms of dry eye disease.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Clark D, Tauber J, Sheppard J, et al. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease. Am J Ophthalmol. 2021. PMID: 33529588. doi:10.1016/j.ajo.2021.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。